Biotech CEOs are now more concerned about insurers than the Food and Drug Administration's regulatory process, reports Luke Zimmerman at Xconomy, drawing on a new survey put out by BayBio, the California Healthcare Institute, and PwC of 157 biotech CEOs in California.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Another Go-Round?

Just Getting Bigger

Investment Boom

Still Concerns

Just Needs Tenants

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.